EuroBiotech—More articles of note


> Shares in GeNeuro fell 65% after its multiple sclerosis candidate failed to cut the number of cerebral Gad-enhancing lesions in a phase 2b trial. The study of the Servier-partnered antibody will continue up to the 12-month readout. But the failure of GNbAC1 to outperform placebo in terms of reducing lesions or relapses has dampened expectations. Statement (PDF)

> AbbVie pulled a phase 1 trial of ABBV-553 prior to enrollment on safety grounds. The action raises doubts about the future of the RORγT inverse agonist, which emerged from AbbVie’s work with French biotech Inventiva. Protocol

> Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab. The Danish drugmaker is currently testing the antibody-drug conjugate in a phase 1/2 trial in patients with solid tumors. Seattle Genetics and Genmab will split all future costs and profits. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Amcure received a €1.8 million grant to support the development of CD44v6 inhibitor AMC303. The German biotech is currently testing the drug in patients with metastatic epithelial tumors in a phase 1/2 trial. Release

> The FDA restated its concerns about the safety and efficacy of Kamada’s inhaled alpha-1 antitrypsin candidate. The Israeli biotech wants to run a phase 3 trial of the formulation but has yet to persuade the FDA to authorize it to proceed with the study. Statement

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.